the firm's post-grant practitioners are some of the most experienced in the country.

Andrew M. Ollis
Eckhard H. Kuesters
Robert W. Downs
Tia D. Fenton
Sameer  Gokhale
Kevin L. Hartman, Ph.D.
Kevin M. McKinley
Jeffrey B. McIntyre
J. Derek  Mason, Ph.D., CLP
Teddy S. Gron
Robert T. Pous
James R. Love
Christopher  Ricciuti
Kasumi  Kanetaka
Dale M. Shaw
Thomas M. Cunningham, Ph.D.
Craig R. Feinberg
Brian B. Darville
David M. Longo, Ph.D.
Ryan W. Smith
Nicholas  Rosa, Ph.D.
Diane  Jones
Marina I. Miller, Ph.D.
Bogdan A. Zinchenko
Norman F. Oblon
Alec M. Royka
Alexander B. Englehart
Yorikatsu  Hohokabe, Ph.D.
Chika (Teranishi) Iitoyo
Tao  Feng, Ph.D.
Yuanyi (Alex) Zhang, Ph.D.
Philippe J.C. Signore, Ph.D.
Frank J. West
Richard D. Kelly
Akihiro  Yamazaki
Jenchieh (Joseph) Yuan
Elissa L. Sanford
John S. Kern
Aldo  Martinez
Kurt M. Berger, Ph.D.
Derek  Lightner, Ph.D.
Yuki  Onoe
Steven B. Chang
John  Sipos
Jay E. Rowe, Jr., Ph.D.
Jianping (James)  Wu
Christopher I. Donahue
Kevin Ross  Davis
Daniel J. Pereira, Ph.D.
Grace E. Kim
Charles L. Gholz
Edwin D. Garlepp
Robert  Tarcu
Arthur I. Neustadt
Long  Phan, Ph.D.
Eric W. Schweibenz
Stefan Uwe  Koschmieder, Ph.D.
Carl E. Schlier
Stephen G. Baxter, Ph.D.
Colin B. Harris


Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our


Get to know our History

Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our


A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.




From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +

Tokyo Office

Telephone: +81-3-6212-0550
Learn More +


Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

FDA Stays Juul Ban, Announces Plan To Implement New Policies

  • July 7, 2022
  • Article

Associated People

Associated Technologies

On June 23, 2022, the FDA banned the sale of Juul’s tobacco-and menthol-flavored products. The agency’s reasoning was that Juul’s applications did not have sufficient toxicological evidence to support the marketing of the products as appropriate for protecting public health.  Juul has long since been on the FDA’s radar for past marketing practices including the marketing of their now-discontinued fruit or candy-like flavors, which were viewed as appealing to minors.  The company secured an emergency stay on June 24, asserting that the FDA did not fully consider its 125,000 page application which purportedly contained studies showing how the products expose users to lower levels of harmful toxins as compared to conventional cigarettes.  Juul also cited political pressure as the FDA’s motivation due to an “inappropriate” level of interference from Congress.

On July 5, 2022, the FDA announced that it would allow Juul products to stay on the shelves pending additional review of evidence related to the company’s application to market the e-cigarettes but noted that their denial order was not rescinded.  The FDA has also announced that it intends to issue a proposed rule in May 2023 and seek  public comment on limiting nicotine in cigarettes to non-addictive levels with the goals of preventing future generations from becoming addicted, as well as helping current smokers quit.

The FDA’s moves have sparked some concern that the strategies may backfire.  One such concern is whether, in response to lower nicotine levels in the products, consumers will just smoke more cigarettes to intake the same amount of nicotine.  Another concern is whether the policies will create a demand for contraband products and an underground market.  Others see the movements as a public health victory and a long overdue measure to prevent minors from picking up the e-cigarette habit.

Legal experts are questioning whether the FDA is prepared to handle the legal challenges that the tobacco industry is likely to bring regarding new nicotine limits.  Pursuant to the Tobacco Control Act, the FDA cannot ban tobacco or mandate no nicotine in cigarettes, but tobacco companies may try to argue the proposed standards are not scientifically achievable.  While it is hard to predict exactly what claims companies could make given that the FDA has not yet issued the proposed rule, disputes over issues like this typically focus on the justification for the rule — whether issues like the creation of a black market have been adequately considered, whether the rule is appropriate for furthering the goal of protecting human health and whether the costs outweigh the benefits.  In this case, one such cost would be the cost for companies to comply with the new standards by reengineering their products and submitting applications for the reformulated products.

In the meantime, we will continue to monitor developments in this area and provide updates on our website.